PARTNERS AND LICENSEES

The Research Institute of McGill University Health Centre (RI-MUHC) in Montreal, Canada
Samaritan Pharmaceuticals has signed a Research Collaboration and Licensing Agreement with The Research Institute of McGill University Health Centre (RI-MUHC) in Montreal, Canada, to advance its promising pipeline into clinical trial status and develop new innovative drug candidates.

During the initial phase of the agreement, RI-MUHC will continue the previous studies led by Dr. Vassilios Papadopoulos, at Georgetown University, who is now the Director of The Research Institute at McGill University Health Centre. Under the Samaritan agreement, RI-MUHC will continue to develop the drug pipeline which was originally developed in the Georgetown University/Samaritan collaboration, and in addition, take potential new drug candidates through the discovery process. Once drug candidates, derived from the collaborative research, are clinically-validated and deemed to hold promise, Samaritan Therapeutics will continue to develop the drug candidate in Canada, while Samaritan Pharmaceuticals will focus on the drug candidate's process through regulatory agencies and its commercialization.

Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, "McGill University Health Centre is extremely impressive. We look forward to continuing our relationship with Dr. Papadopoulos, Dr. Lecanu and the rest of the scientists that have transferred to McGill. As patents expire and industry innovation declines, we feel this strategic alliance will help us to keep our pipeline fresh and stay ahead of the curve, in addition to the financial benefits we hope to receive by accomplishing research in Canada."

Pharmplaz, Ltd., Athlone, Ireland
On March 28, 2007, Samaritan and Pharmaplaz announced they have a collaboration to develop and commercialize SP-01A, an "oral" HIV entry inhibitor, which has demonstrated safety and efficacy in Phase II human clinical trials. Under the terms of the agreement, Pharmaplaz is required to pay Samaritan $10 million upfront. The first payment of $1.4 million was received on March 28, 2007, and the remaining $8.6 million is required to be paid on September 16, 2007. Pharmaplaz will be responsible for clinical development, clinical trial costs and manufacturing. Upon successful commercialization, Samaritan and Pharmaplaz will co-market SP-01A and will share 50-50, in its revenue royalty stream. Samaritan is responsible for all patent expenses, including filing, prosecution, and enforcement expenses.

Pharmaplaz is a fully integrated pharmaceutical company located in Athlone, Ireland. Pharmaplaz develops patented pharmaceutical technologies and products, and has expertise in initial research, process development, clinical trials, regulatory submissions and product manufacturing. Pharmaplaz, in addition, offers facilities for the development of products and processes in life sciences, and can also provide additional support with government grant aid and regulatory affairs.

Shire Pharmaceuticals, Basingstoke, UK
On March 1, 2007, Samaritan executed a two-year exclusive licensing deal with Shire Pharmaceuticals for the marketing of Elaprase in Greece and Cyprus. The product shall be supplied on a named patient basis until the conclusion of the negotiations relating to the pricing and reimbursement of Elaprase in the territories with the relevant regulatory authorities.

Founded in 1986, Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence, where effective targeting of prescribers allows maximization of sales by a relatively small but high quality sales force.

Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

Fusion Capital, Chicago, IL
Fusion Capital is an innovative, broad-based investment fund offering a wide range of investment products, from special situation financing to long-term strategic capital. Fusion is dedicated to meeting the business needs of its partner companies.

Fusion Capital invests in publicly traded companies who demonstrate a clear business vision and the ability to execute on this vision; making investments of between $5 to $50 million in each partner company.

Fusion's knowledge, experience and responsiveness allow us to structure innovative and creative investments that align our interests with those of our partner companies. We believe that making mutually beneficial investments leads to long-term profitable relationships.

Molteni Pharmaceuticals, Florence, Italy
On January 1, 2007, Samaritan executed a four-year (with two-year automatic renewals) exclusive licensing agreement with Molteni Farmaceutici for the marketing of Mepivamol, Methadone, Morphine Sulphate, Naloxone, Naltrexone, and Oramorph in Greece and Cyprus.

Molteni is rich in history with over a century of experience beginning with the opening of its manufacturing facility at the Molteni Pharmacy Laboratory located in the historic center of Florence, Italy. The strategic therapeutic areas on which Molteni makes an effort for trading new alliances are concentrated on Analgesia, Anesthesia and Drug Addition Therapy.

Metastatin Pharmaceuticals, Bethesda, MD
On March 1, 2007, Samaritan announced that we had completed our acquisition of Metastatin Pharmaceuticals, a biopharmaceutical company engaged in the development of cytostatic and anti-metastatic therapies for the management of cancer. As part of the acquisition of Metastatin, Samaritan acquired the following patent rights:

Patent No.	Description
08/400,084	Methods and Compositions for Inhibiting Metastasis of Epithelial Cell-Derived Cancers (US)
122266	Method and a Kit for Determining Metastatic Potential of a Tumor of Epithelial Cell Origin (Israel)
08/486,203	Determining Evasiveness of Prostatic Adenocarcinoma (US)
08/658,796	Methods and Compositions for Inhibiting Metastasis of Epithelial Cell-Derived Cancer (US)
08/966,196	Kit for Identifying Prostatic Intraepithelial Neoplasia (PIN) (US)
09/512,385	Uteroglobin Therapy for Epithelial Cell Cancer (US)
09/556,468	Non-Steroidal Anti-Inflammatory Agent Therapy for Epithelial Cell Cancer (US)
09/556,467	Uteroglobin Gene Therapy for Epithelial Cell Cancer (US)
09/433,092	Pharmaceutical Compositions, Methods and Kits for Treatment and Diagnosis of Breast Cancer (US)
08/987,502	Methods for Inhibiting Metastasis (US)
08/987,505	Pharmaceutical Compositions, Methods and Kits for Treatment and Diagnosis of Lung Cancer (US)

Three Rivers Pharmaceuticals, Cranberry Township, PA
On December 12, 2005, Samaritan signed a ten-year (with five-year automatic renewals) exclusive licensing agreement with Three Rivers Pharmaceuticals, Inc. for the marketing of Amphocil, a prescription drug in Greece; authorization is pending for Cyprus.

Established in 2000, Three Rivers Pharmaceuticals(R) devotes its efforts and resources to developing, manufacturing, and marketing pharmaceutical therapies which are indicated for diseases/medical conditions requiring specialized treatment. Currently, Three Rivers Pharmaceuticals markets prescription drugs in both the U.S. and internationally, in the therapeutic categories of antiviral and antifungal agents.

Three Rivers has continued to expand its product line into the branded market with the acquisition of AMPHOTEC/AMPHOCIL(R) in May of 2005. This product is currently being marketed in over 40 countries worldwide.

Samaritan Europe, Athens, Greece
Samaritan Pharmaceuticals became a global organization after creating and implementing Samaritan Pharmaceuticals Europe as a marketing and distribution arm in Greece, Eastern Europe and the MIddle East. Samaritan Europe is strategically headquartered in Athens, Greece thus providing access to the following markets; Poland, Czech, Slovakia, Hungary, Romania, Slovenia, Croatia, Bosnia, Yugoslavia, Bulgaria, F.Y.R.O.M., Albania, Greece, Turkey, Egypt Syria and Cyprus.

The main focus of Samaritan Europe includes:

In-licensing and marketing drugs to selected regions while simultaneously building a delivery infrastructure through hospitals, governments and medical providers.

To-date Samaritan Pharmaceuticals Europe has In-licensed 9 revenue producing, branded, prescription drugs;

Shire's Elaprase® Three River's Amphocil® Ony's Infasurf® Molteni's Oramorph® Molteni's Morphine Sulphate® Molteni's Methadone HCL® Molteni's Naloxone Molteni® Molteni's Naltrexone HCL® Molteni's Mepivamol®

European Clinical Trials and Regulatory Approval Samaritan Europe will be responsible for clinical trials and regulatory approval of all drug candidates in Europe as a whole, with a focus on low-cost clinical trials in southeast Europe, Asia, Africa and other countries. Samaritan Europe's first task will be to initiate Samaritan's latest stage HIV drug through European clinical trials and regulatory approval with the FDA's European counterpart, the European Agency for the Evaluation of Medicinal Products (EMEA).

Samaritan Ireland, Athlone, Ireland
Samaritan Pharmaceuticals, Ireland manages the manufacturing of Samaritan Pharmaceuticals drugs. Currently, Samaritan Pharmaceuticals, Ireland works with Pharmaplaz on the manufacturing of SP-01A. This creates a virtual in-house facility eliminating the hiring of contract manufacturers, and savings as much as $500,000 per drug. Attractive tax breaks have turned Ireland into a major drug manufacturing center, with 13 of the top 15 drug makers now in Ireland.

Samaritan Pharmaceuticals, Ireland is also currently trying to create relationships with Irish universities to conduct preclinical research.